Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGC (Transdermal Glucosamine Cream) is a topical formulation developed by Lynk Biotechnologies for the treatment of knee osteoarthritis. It utilizes a proprietary transdermal delivery technology to deliver glucosamine sulfate directly through the skin to the synovial fluid of the affected joint. Glucosamine is a naturally occurring amino sugar that serves as a critical building block for the synthesis of glycosaminoglycans and proteoglycans, which are essential components of the cartilage matrix. By delivering the active ingredient topically, TGC aims to provide targeted relief and support cartilage health while bypassing the gastrointestinal metabolism and potential systemic side effects associated with oral glucosamine administration. The product is available in various concentrations, including a 10% high-strength version.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TGC.